{"id":77734,"date":"2026-09-01T12:05:36","date_gmt":"2026-09-01T04:05:36","guid":{"rendered":"https:\/\/flcube.com\/?p=77734"},"modified":"2026-09-01T12:05:37","modified_gmt":"2026-09-01T04:05:37","slug":"eli-lilly-to-acquire-merida-biosciences-for-up-to-usd-2-875-billion-adding-mer511-precision-autoantibody-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=77734","title":{"rendered":"Eli Lilly to Acquire Merida Biosciences for Up to USD 2.875 Billion, Adding MER511 Precision Autoantibody Platform"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Eli Lilly (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/LLY:NYSE\">NYSE: LLY<\/a>)<\/strong> and <strong>Merida Biosciences<\/strong>, a biotechnology company advancing a new class of precision therapeutics for serious autoimmune and allergic diseases, announced a definitive agreement under which <strong>Lilly<\/strong> will acquire <strong>Merida<\/strong>. The all-cash transaction, valued at up to <strong>USD 2.875 billion<\/strong> inclusive of upfront and contingent milestone payments, brings <strong>Lilly<\/strong> a novel biologics platform that selectively degrades pathogenic autoantibodies \u2014 anchored by lead Phase 1 candidate <strong>MER511<\/strong> in <strong>Graves&#8217; disease<\/strong> and <strong>thyroid eye disease (TED)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-deal-overview\" class=\"wp-block-heading\">Deal Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Acquirer<\/td><td><strong>Eli Lilly (NYSE: LLY)<\/strong><\/td><\/tr><tr><td>Target<\/td><td><strong>Merida Biosciences<\/strong><\/td><\/tr><tr><td>Consideration<\/td><td>Up to <strong>USD 2.875 billion<\/strong> in cash (upfront + contingent milestones)<\/td><\/tr><tr><td>Announcement Date<\/td><td><strong>31 Aug 2026<\/strong><\/td><\/tr><tr><td>Expected Close<\/td><td><strong>Q4 2026<\/strong>, subject to customary closing conditions including regulatory approvals<\/td><\/tr><tr><td>Strategic Focus<\/td><td>Precision autoantibody-degrading biologics for autoimmune, allergic, and kidney diseases<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-pipeline-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Pipeline Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Concept:<\/strong> Biologics that selectively degrade pathogenic autoantibodies \u2014 the root cause of many immune-mediated diseases \u2014 while preserving normal immune function, unlike broad immunosuppression<\/li>\n\n\n\n<li><strong>Lead Candidate:<\/strong> <strong>MER511<\/strong>, in <strong>Phase 1<\/strong> development for <strong>Graves&#8217; disease<\/strong> and <strong>thyroid eye disease (TED)<\/strong><\/li>\n\n\n\n<li><strong>Allergy Franchise:<\/strong> <strong>MER769<\/strong>, targeting allergic conditions<\/li>\n\n\n\n<li><strong>Renal Programs:<\/strong> Earlier-stage candidates for kidney diseases including <strong>membranous nephropathy<\/strong><\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Indication<\/th><th>Stage<\/th><\/tr><\/thead><tbody><tr><td><strong>MER511<\/strong><\/td><td>Graves&#8217; disease, thyroid eye disease (TED)<\/td><td>Phase 1<\/td><\/tr><tr><td><strong>MER769<\/strong><\/td><td>Allergic conditions<\/td><td>Preclinical\/early development<\/td><\/tr><tr><td>Undisclosed programs<\/td><td>Membranous nephropathy and other kidney diseases<\/td><td>Early stage<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Precision Over Immunosuppression:<\/strong> The autoantibody-degradation mechanism offers a differentiated alternative to broad immunosuppressants \u2014 potentially widening the treatable patient pool in antibody-driven diseases with high unmet need<\/li>\n\n\n\n<li><strong>Immunology Portfolio Depth:<\/strong> The acquisition reinforces <strong>Eli Lilly<\/strong>&#8216;s push beyond metabolic disease into immunology, adding a platform rather than a single asset<\/li>\n\n\n\n<li><strong>TED Synergies:<\/strong> <strong>MER511<\/strong>&#8216;s focus on <strong>Graves&#8217; disease<\/strong> and <strong>TED<\/strong> complements the commercial infrastructure Lilly has built in endocrine and ophthalmic-adjacent indications<\/li>\n\n\n\n<li><strong>Optionality Beyond Lead Asset:<\/strong> <strong>MER769<\/strong> and renal programs (including <strong>membranous nephropathy<\/strong>) provide multi-vertical upside against the USD 2.875 billion consideration<\/li>\n\n\n\n<li><strong>Near-Term Catalyst:<\/strong> Transaction expected to close in <strong>Q4 2026<\/strong> pending regulatory approvals; post-close development milestones will be the key value drivers to watch<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2014 This brief contains forward-looking statements regarding the proposed acquisition, pipeline development, and expected closing that involve risks and uncertainties, including regulatory approvals. Actual results may differ materially. Nothing herein constitutes investment advice.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly (NYSE: LLY) and Merida Biosciences, a biotechnology company advancing a new class of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[65,199,4916,911],"class_list":["post-77734","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-auto-immune","tag-eli-lilly","tag-merida-biosciences","tag-nyse-lly"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly to Acquire Merida Biosciences for Up to USD 2.875 Billion, Adding MER511 Precision Autoantibody Platform - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly (NYSE: LLY) and Merida Biosciences, a biotechnology company advancing a new class of precision therapeutics for serious autoimmune and allergic diseases, announced a definitive agreement under which Lilly will acquire Merida. The all-cash transaction, valued at up to USD 2.875 billion inclusive of upfront and contingent milestone payments, brings Lilly a novel biologics platform that selectively degrades pathogenic autoantibodies \u2014 anchored by lead Phase 1 candidate MER511 in Graves&#039; disease and thyroid eye disease (TED).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=77734\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly to Acquire Merida Biosciences for Up to USD 2.875 Billion, Adding MER511 Precision Autoantibody Platform\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly (NYSE: LLY) and Merida Biosciences, a biotechnology company advancing a new class of precision therapeutics for serious autoimmune and allergic diseases, announced a definitive agreement under which Lilly will acquire Merida. The all-cash transaction, valued at up to USD 2.875 billion inclusive of upfront and contingent milestone payments, brings Lilly a novel biologics platform that selectively degrades pathogenic autoantibodies \u2014 anchored by lead Phase 1 candidate MER511 in Graves&#039; disease and thyroid eye disease (TED).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=77734\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-01T04:05:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-01T04:05:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77734#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77734\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly to Acquire Merida Biosciences for Up to USD 2.875 Billion, Adding MER511 Precision Autoantibody Platform\",\"datePublished\":\"2026-09-01T04:05:36+00:00\",\"dateModified\":\"2026-09-01T04:05:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77734\"},\"wordCount\":378,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Eli Lilly\",\"Merida Biosciences\",\"NYSE: LLY\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77734#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77734\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=77734\",\"name\":\"Eli Lilly to Acquire Merida Biosciences for Up to USD 2.875 Billion, Adding MER511 Precision Autoantibody Platform - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-09-01T04:05:36+00:00\",\"dateModified\":\"2026-09-01T04:05:37+00:00\",\"description\":\"Eli Lilly (NYSE: LLY) and Merida Biosciences, a biotechnology company advancing a new class of precision therapeutics for serious autoimmune and allergic diseases, announced a definitive agreement under which Lilly will acquire Merida. The all-cash transaction, valued at up to USD 2.875 billion inclusive of upfront and contingent milestone payments, brings Lilly a novel biologics platform that selectively degrades pathogenic autoantibodies \u2014 anchored by lead Phase 1 candidate MER511 in Graves' disease and thyroid eye disease (TED).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77734#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77734\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77734#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly to Acquire Merida Biosciences for Up to USD 2.875 Billion, Adding MER511 Precision Autoantibody Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly to Acquire Merida Biosciences for Up to USD 2.875 Billion, Adding MER511 Precision Autoantibody Platform - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly (NYSE: LLY) and Merida Biosciences, a biotechnology company advancing a new class of precision therapeutics for serious autoimmune and allergic diseases, announced a definitive agreement under which Lilly will acquire Merida. The all-cash transaction, valued at up to USD 2.875 billion inclusive of upfront and contingent milestone payments, brings Lilly a novel biologics platform that selectively degrades pathogenic autoantibodies \u2014 anchored by lead Phase 1 candidate MER511 in Graves' disease and thyroid eye disease (TED).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=77734","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly to Acquire Merida Biosciences for Up to USD 2.875 Billion, Adding MER511 Precision Autoantibody Platform","og_description":"Eli Lilly (NYSE: LLY) and Merida Biosciences, a biotechnology company advancing a new class of precision therapeutics for serious autoimmune and allergic diseases, announced a definitive agreement under which Lilly will acquire Merida. The all-cash transaction, valued at up to USD 2.875 billion inclusive of upfront and contingent milestone payments, brings Lilly a novel biologics platform that selectively degrades pathogenic autoantibodies \u2014 anchored by lead Phase 1 candidate MER511 in Graves' disease and thyroid eye disease (TED).","og_url":"https:\/\/flcube.com\/?p=77734","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-01T04:05:36+00:00","article_modified_time":"2026-09-01T04:05:37+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=77734#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=77734"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly to Acquire Merida Biosciences for Up to USD 2.875 Billion, Adding MER511 Precision Autoantibody Platform","datePublished":"2026-09-01T04:05:36+00:00","dateModified":"2026-09-01T04:05:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=77734"},"wordCount":378,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Eli Lilly","Merida Biosciences","NYSE: LLY"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=77734#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=77734","url":"https:\/\/flcube.com\/?p=77734","name":"Eli Lilly to Acquire Merida Biosciences for Up to USD 2.875 Billion, Adding MER511 Precision Autoantibody Platform - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-09-01T04:05:36+00:00","dateModified":"2026-09-01T04:05:37+00:00","description":"Eli Lilly (NYSE: LLY) and Merida Biosciences, a biotechnology company advancing a new class of precision therapeutics for serious autoimmune and allergic diseases, announced a definitive agreement under which Lilly will acquire Merida. The all-cash transaction, valued at up to USD 2.875 billion inclusive of upfront and contingent milestone payments, brings Lilly a novel biologics platform that selectively degrades pathogenic autoantibodies \u2014 anchored by lead Phase 1 candidate MER511 in Graves' disease and thyroid eye disease (TED).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=77734#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=77734"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=77734#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly to Acquire Merida Biosciences for Up to USD 2.875 Billion, Adding MER511 Precision Autoantibody Platform"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77734","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=77734"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77734\/revisions"}],"predecessor-version":[{"id":77736,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77734\/revisions\/77736"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=77734"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=77734"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=77734"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}